Prostate Cancer

Improved outcomes with lutetium Lu 177 vipivotide tetraxetan vs ARPI change supported prior treatment with abiraterone vs enzalutamide in mCRPC.

Data support using 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

Administering high-intensity focused ultrasound could be a noninferior treatment option for patients with localized prostate cancer, according to a prospective trial.

Apalutamide with androgen deprivation therapy following radical prostatectomy led to a biochemical recurrence-free survival rate of 100% after 2 years among patients with high-risk prostate cancer.

A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.

In an interview with Targeted Oncology, Kim N. Chi, MD, FRCPC, discussed the MAGNITUDE trial results, including patient-reported outcomes, in patients with BRCA-positive mCRPC.

In an interview with Targeted Oncology, Nasir Chaudry, MD, discussed the evolving landscape of prostate cancer treatment, driven by new research.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.

The National Comprehensive Cancer Network has included ArteraAI in its clinical practice guidelines as a predictive test for localized prostate cancer.

The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.

In an interview with Targeted Oncology, Clara Hwang, MD, discussed the notable differences in molecular alterations observed in the retrospective cohort study among Black men with metastatic castration-resistant prostate cancer compared with White men.

In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the findings from her analysis of the Language of Respect guidelines adopted by the American Society of Clinical Oncology and how well they are followed in prostate cancer abstracts.

Individuals diagnosed with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) receiving olaparib face a critical requirement for timely and consistent genetic testing to enhance treatment outcomes.

The combination of olaparib and abiraterone acetate resulted in a postponement of disease progression and enhanced outcomes for individuals with mutations in BRCA, ATM, and CDK12 in metastatic castration-resistant prostate cancer.

A post hoc sensitivity analysis that counted use of subsequent therapies in patients censored from primary overall survival follow-up favored darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Regarding safety, the investigators did not observe any grade 3 or 4 adverse events during the study.

A higher dose of radiation therapy led to longer progression-free, cancer-specific, and overall survival, compared with the standard dose, in combination with long-term ADT in patients with high-risk prostate cancer.

Research suggests that combining cabozantinib with atezolizumab could emerge as a promising alternative for individuals facing metastatic castration-resistant prostate cancer that has advanced after novel hormonal therapy.

Oncological outcomes improved with the addition of abiraterone acetate (Zytiga) plus prednisone (AAP) and apalutamide (Erleada) after radical prostatectomy and did not significantly affect health-related quality of life.

A promising new treatment combination of frontline olaparib plus abiraterone/prednisone has emerged for advanced prostate cancer with specific genetic alterations.

Prior treatment with external beam radiation therapy did not increase incidence of hematological toxicity relative to the overall population of patients with metastatic castration-resistant prostate cancer treated with radium-223.

While germline and somatic testing is standard of care in the metastatic castration-resistant prostate cancer setting, it is still underutilized in the real world, leading to negative impacts on therapeutic offerings.

Patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus androgen deprivation therapy and docetaxel had lower rates of hospitalizations but marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy, and docetaxel.

Nasir Chaudry, MD, discusses treatment decisions for patients with prostate cancer and the importance of individualized treatment based on the specific case and patient preferences.

Rucaparib showed a significant improvement in progression-free survival compared with docetaxel in metastatic castration- resistant prostate cancer.

The phase 1/2 CaRe PC trial evaluating INKmune, a biologic therapy, in male patients with metastatic castration-resistant prostate cancer has dosed its first patient.

No serious adverse events or dose-limiting toxicities were observed in the phase 1/2 trial of the antibody drug conjugate ARX517.

A patient with prostate cancer in the SECuRE trial treated with 2 cycles of 67Cu-SAR-bisPSMA at the 8GBq dose level has achieved undetectable prostate specific antigen levels.

In an interview with Targeted Oncology, Neeraj Agarwal, MD, discussed findings from the TITAN trial which were presented at ESMO 2023.